Page 1

AC Immune PRESS RELEASE • • AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update Reported potent interim immunogenicity results for anti - pTau Alzheimer's vaccine in ongoing Phase 1b / 2a study , which support further development into Phase 2/3 Initiated first - in - human clinical study for next - generation alpha - synuclein PET diagnostic with results expected in Q3 2021 Advanced multiple candidates targeting the NLRP3 inflammasome pathway for CNS and non - CNS indications Strong financial position of CHF 216.1 million in cash ensures the Company is fully financed through at least Q1 2024 Lausanne , Switzerland , April 28 , 2021 AC Immune SA ( NASDAQ : ACIU ) , a clinical - stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases , today reported its financial results for the quarter ended March 31 , 2021. The Company also provided an overview of its recent clinical and corporate highlights and anticipated milestones for 2021 . Prof. Andrea Pfeifer , CEO of AC Immune SA , commented : " Our clinical and R & D accomplishments over the last quarter serve to strengthen our leadership in precision medicine for neurodegenerative diseases . Encouraging clinical results from both of our Alzheimer's vaccine programs further reinforce our belief that early intervention , and ultimately prevention , using vaccines represents a key strategy in neurodegenerative diseases . To enable this strategy , we are advancing our suite of novel diagnostics , such as our alpha - synuclein imaging agent , which recently entered the clinic in Parkinson's disease . Our vision is to address the heterogeneity of neurodegenerative diseases by pairing earlier , more accurate diagnosis with highly selective treatments that address the right proteinopathy , in the right patient , at the right time . " Prof. Pfeifer continued : “ We are poised to achieve four additional clinical readouts in 2021 , as we continue progressing our first - in - class preclinical programs addressing alpha - synuclein , TDP - 43 , and NLRP3 - ASC towards the clinic , driving significant future value creation . Q1 2021 Highlights Clinical and R & D - - Reported encouraging top line results from a first - of - its - kind Phase 1b study of anti - Abeta vaccine candidate ACI - 24 in people with Down syndrome ( DS ) . These results support further development in Down syndrome - related Alzheimer's disease ( AD ) . AC Immune also reported promising preclinical results for an optimized anti - Abeta vaccine formulation , for which it expects to file an investigational new drug application ( IND ) in Q4 2021 . Reported promising interim Phase 1b / 2a results for ACI - 35.030 , a novel anti - phospho - Tau ( pTau ) vaccine candidate , showing strong safety and high titers of antigen - specific antibodies in 100 % of older patients with early Alzheimer's disease . The study is currently 1/8